NCT03365635View on ClinicalTrials.gov

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 22, 2019

Primary Completion Date

May 1, 2020

Study Completion Date

September 1, 2020

Conditions
Hepatitis CHemodialysisNosocomial Infection
Interventions
DRUG

Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]

Same as described in arm description

Trial Locations (1)

19428

Penn Presbyterian Medical Center, Philadelphia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C | Biotech Hunter | Biotech Hunter